about
Transcriptional Targeting in Cancer Gene TherapyTreatment of terminal peritoneal carcinomatosis by a transducible p53-activating peptideImmunologic aspect of ovarian cancer and p53 as tumor antigen.Combinations in multimodality treatments and clinical outcomes during cancerOptimizing targeted gene delivery: chemical modification of viral vectors and synthesis of artificial virus vector systemsA modified hTERT promoter-directed oncolytic adenovirus replication with concurrent inhibition of TGFbeta signaling for breast cancer therapyApplications of plasmid electrotransfer.Prodrug converting enzyme gene delivery by L. monocytogenes.Research on the interaction between tubeimoside 1 and HepG2 cells using the microscopic imaging and fluorescent spectra methodPET imaging of heat-inducible suicide gene expression in mice bearing head and neck squamous cell carcinoma xenograftsDual cancer-specific targeting strategy cures primary and distant breast carcinomas in nude mice.The promise of microRNA replacement therapy.Lipid-like nanomaterials for simultaneous gene expression and silencing in vivo.Ovarian cancer gene therapy using HPV-16 pseudovirion carrying the HSV-tk geneEnhancing polyethylenimine's delivery of plasmid DNA into mammalian cells.Combined therapy with cytokine-induced killer cells and oncolytic adenovirus expressing IL-12 induce enhanced antitumor activity in liver tumor modelCell transfection in vitro and in vivo with nontoxic TAT peptide-liposome-DNA complexes.Intravascular adenoviral agents in cancer patients: lessons from clinical trials.Armed therapeutic viruses: strategies and challenges to arming oncolytic viruses with therapeutic genes.Overview of the clinical efficacy of investigational anticancer drugs.Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice.Species D human adenovirus type 9 exhibits better virus-spread ability for antitumor efficacy among alternative serotypes.Therapeutic properties of a vector carrying the HSV thymidine kinase and GM-CSF genes and delivered as a complex with a cationic copolymer.Quantification of functionalised gold nanoparticle-targeted knockdown of gene expression in HeLa cellsConjugation to gold nanoparticles enhances polyethylenimine's transfer of plasmid DNA into mammalian cells.Somatostatin receptor based imaging and radionuclide therapy.Transcriptionally targeted gene therapy to detect and treat cancer.Strategies for reversing drug resistance.Gene therapy for gastric cancer: a review.TRAIL and apoptosis induction by TNF-family death receptors.Gene therapy for carcinoma of the breast.Cancer metastasis therapeutic targets and drug discovery: emerging small-molecule protein kinase inhibitors.Development of herpesvirus-based episomally maintained gene delivery vectors.Targeted Regression of Hepatocellular Carcinoma by Cancer-Specific RNA Replacement through MicroRNA RegulationBiodegradable cationic polymeric nanocapsules for overcoming multidrug resistance and enabling drug-gene co-delivery to cancer cells.A fungicide-responsive kinase as a tool for synthetic cell fate regulation.Graphene: a versatile nanoplatform for biomedical applications.Therapeutic gene delivery and transfection in human pancreatic cancer cells using epidermal growth factor receptor-targeted gelatin nanoparticles.Future directions and treatment strategies for head and neck squamous cell carcinomasTherapy of cancer by cytokines mediated by gene therapy approach.
P2860
Q24791038-8493F843-897F-410D-B547-3F77EFA146B8Q24796110-8B972FC0-E05A-4D86-A4C7-E5B6C01C64B4Q24814703-B8AA5EA0-C663-4DA9-8CD9-E780D7A79E3EQ28468623-A59BC05C-FF3A-455D-A353-6CBB91D2FCA5Q28476268-7B93ED76-356B-4593-8BFE-6464172A8F7AQ30434613-646FB7AF-3B47-4B91-833B-F0350A6E8BA1Q33186308-69E84D08-29F6-45D6-A3AA-031C29DDDF94Q33327560-8A6E1DB4-0779-45C9-AD3D-4DDCDF09E85BQ33738107-91F3C3E0-67F4-4EF0-807E-B2B2A3E694E0Q34018755-202AC0D6-7C03-40BD-B0F9-9C71C6DAE5ACQ34048220-FE21C56B-F570-4CAC-A4A1-4A1E2FC4B12AQ34134295-7041CA4C-B941-4D48-8878-75D77A6A086CQ34160892-A918D73F-C63D-45B3-A8E7-DCBF7B2A34BEQ34345491-1EEB798B-7CC1-4370-A4F8-0CBC23C4BB19Q34378581-E78EA1B4-7FA2-4E8A-B4C5-B9973A58CA5DQ34427459-DA8C3683-D3BC-48AE-B98C-636767EDEE44Q34762768-58874D9C-558D-4E99-855F-07AD9CC94AD0Q35043094-213BA4E2-B701-43B2-B0B9-9457FD35D854Q35043106-0DAE322E-F483-4B1E-A80A-8D8B44C6E123Q35067125-20D1EEB6-2E87-4BF0-8C19-88E6340A6A7DQ35086711-36293464-04FC-4143-8389-D9B5FA6F8F8DQ35087653-750D27F1-63A7-446E-AE71-07AE51A0A633Q35176800-1D9CC3FA-96EE-447B-B97A-28100E4C06ABQ35187635-4BF6FFD1-6571-41BD-B880-7E1ACF14821DQ35234161-5942E3BC-5DE6-4293-B207-7F11B2B628B0Q35296661-FF901C9C-98A2-4B10-99EA-D134EFCA7D4EQ35558678-2D628FC7-B1C7-4241-ADD0-B9FB687E71FCQ35567287-30A2A386-EBB9-48C9-9019-57EED051483EQ35579112-562592ED-C013-4D5F-B196-14965D2E5405Q35591708-202A6FFD-29D1-4DB3-A17F-DDFEB9F52D04Q35609061-CBF9DD9D-0A3B-480F-BFC8-7AE837A48DFDQ35609713-C598D193-6119-4B76-8481-548C1CA38DE2Q35753517-26756FC2-BDEB-42A9-9220-2E229740EB18Q35865503-05DCF100-453C-465A-A12A-B9EBC839A5C7Q35908348-F67ECB3B-45C4-4DCA-BE35-0ABC533D014BQ35961972-C1B0D50F-D4BD-4979-AC69-BEFBAA6C9C14Q36035392-60CBC1D9-37E3-4F97-BC1C-91005D019AA0Q36104491-89F12901-6119-401D-AD32-C96E849C324EQ36177257-8A276011-A0D7-4AB5-BD24-35DB7FB634DBQ36394987-CCD2F455-5DA2-4563-904E-1A5DF52F66C2
P2860
description
2001 nî lūn-bûn
@nan
2001 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Cancer gene therapy: fringe or cutting edge?
@ast
Cancer gene therapy: fringe or cutting edge?
@en
Cancer gene therapy: fringe or cutting edge?
@nl
type
label
Cancer gene therapy: fringe or cutting edge?
@ast
Cancer gene therapy: fringe or cutting edge?
@en
Cancer gene therapy: fringe or cutting edge?
@nl
prefLabel
Cancer gene therapy: fringe or cutting edge?
@ast
Cancer gene therapy: fringe or cutting edge?
@en
Cancer gene therapy: fringe or cutting edge?
@nl
P356
P1476
Cancer gene therapy: fringe or cutting edge?
@en
P2093
McCormick F
P2888
P304
P356
10.1038/35101008
P407
P577
2001-11-01T00:00:00Z
P5875
P6179
1032458985